sábado, 8 de agosto de 2020

Disaster Lit® Database Daily Updates | COVID-19 | 1

Disaster Lit® Database Daily Updates

Disaster Information and Emergency Response

08/06/2020 12:00 AM EDT

Source: World Health Organization (WHO). Published: 8/6/2020. This six-page document provides information about the COVID-19 Vaccines Global Access (COVAX) Facility, where countries have the opportunity to benefit from a portfolio of vaccine candidates so that their populations can have early access to effective vaccines. (PDF)
08/05/2020 12:00 AM EDT

Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 8/5/2020. This web page outlines considerations for modifying contact tracing protocols during the COVID-19 pandemic to maximize efficient use of limited resources. It is for CDC country offices, ministries of health, sub-national public health authorities, and other implementing partners in non-U.S. settings. (Text)
08/04/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 8/4/2020. During the COVID-19 pandemic, health care facilities and providers have reported that care of ventilated patients can be complicated by the need to discard containers of medications before they are fully administered because of the in-use time specified on the FDA-approved label. This web page provides information to minimize the likelihood of physicochemical degradation or microbial proliferation during use in situations where a provider is considering use beyond the labeled in-use time for the products listed on this page. (Text)
08/03/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 8/3/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of a Molecular LDT COVID-19 Authorized Test called the Wren Laboratories COVID-19 PCR Test that has been issued an Emergency Use Authorization (EUA) by the FDA. The Molecular LDT COVID-19 Authorized Test is authorized for use on certain respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
08/03/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 8/3/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Ethos Laboratories SARS-CoV-2 MALDI-TOF Assay that has been issued an Emergency Use Authorization (EUA) by the FDA. The Ethos Laboratories SARS-CoV-2 MALDI-TOF Assay is authorized for use on certain respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
08/03/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 8/3/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of a Molecular LDT COVID-19 Authorized Test called the Cleveland Clinic SARS-CoV-2 Assay that has been issued an Emergency Use Authorization (EUA) by the FDA. The Molecular LDT COVID-19 Authorized Test is authorized for use on certain respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
08/03/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 8/3/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Poplar SARS-CoV-2 TMA Pooling assay. The Poplar SARS-CoV-2 TMA Pooling assay is authorized for use with certain respiratory specimens collected from individuals who are suspected of COVID-19 by their healthcare provider. (PDF)
08/03/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 8/3/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Impella Left Ventricular (LV) Support Systems. The Impella LV Support Systems are authorized for emergency use by healthcare providers (HCP) in the hospital setting for providing temporary LV unloading and support to treat critical care patients with confirmed COVID-19 infection who are undergoing extracorporeal membrane oxygenation (ECMO) treatment and who develop pulmonary edema while on veno-arterial (V-A) ECMO support or late cardiac decompensation from myocarditis while on veno-venous (V-V) ECMO support. (PDF)
07/31/2020 12:00 AM EDT

Source: American Hospital Association (AHA). Published: 7/31/2020. Speakers in this 50-minute webinar share strategies on leveraging race, ethnicity and language (REaL) data collection, stratification, and utilization during the COVID-19 pandemic. (Video or Multimedia)
07/17/2020 12:00 AM EDT

Source: Government of Canada. Published: 7/17/2020. This web page provides care guidance specific to the COVID-19 pandemic in Canadian homes/facilities where older adults require continuous supervised care, including professional health services, personal care, and other services such as meals, laundry, and housekeeping. (Text)
07/10/2020 12:00 AM EDT

Source: National Indian Health Board (NIHB). Published: 7/10/2020. This one-hour, 11-minute webinar explores how contact tracing is being carried out in Indian Country during the COVID-19 pandemic, and how case investigation and contact tracing are core methods used by Tribal, local, and state health departments for disease control and preventing the spread of COVID-19. (Video or Multimedia)
07/01/2020 12:00 AM EDT

Source: Substance Abuse and Mental Health Services Administration (SAMHSA). Published: 7/2020. This 34-page issue brief presents data on prevalence of opioid misuse and death rates in the Hispanic/Latino population; contextual factors and challenges to prevention and treatment; innovative outreach and engagement strategies to connect people to evidence-based treatment; and the importance of community voice. (PDF)
06/22/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 6/22/2020. This nine-page document provides answers to frequently asked questions about regulatory and policy issues related to medical device development for the duration of the COVID-19 public health emergency. (PDF)
06/18/2020 12:00 AM EDT

Source: World Bank. Published: 6/18/2020. This five-page brief from the World Bank, London School of Hygiene & Tropical Medicine, Harvard Kennedy School, and Project Clear provides guidelines and principles to help governments develop national communications strategies for behavior change during the COVID-19 pandemic. (PDF)
06/11/2020 12:00 AM EDT

Source: Association of State and Territorial Health Officials (ASTHO). Published: 6/11/2020. This 58-minute webinar highlights the use of the Overdose Detection Mapping Application Program (ODMAP), a syndromic surveillance application that serves as a collaborative and centralized platform for all disciplines responding to the opioid crisis, and its use during the COVID-19 pandemic. (Video or Multimedia)
06/09/2020 12:00 AM EDT

Source: Emory University School of Medicine. Published: 6/9/2020. This web page provides guidance when users to click on "Conserve" if their personal protective equipment (PPE) supplies are low in the inpatient setting; "Standard" if PPE supplies are sufficient in the inpatient setting. Click on "Ambulatory" if you are in an outpatient setting; "Emergency Department" if you are serving there; "Operating Room" if you are serving there. (Text)
06/01/2020 12:00 AM EDT

Source: Academic Network for Sexual and Reproductive Health and Rights Policy [Ghent University] (ANSER). Published: 6/2020. I-SHARE is a cross-sectional, multi-country study on sexual and reproductive health well-being in the time of the COVID-19 crisis. The survey instrument is online-based, administered by local organizations in participating countries (34 countries to date), and designed to assess the impact of social distancing measures on sexual risk behaviors, intimate partner violence, and access to essential reproductive health services. The data collected from the survey are divided into the following sections: socio-demographics, compliance with social-distancing measures, couple and family relationships, sexual behavior, access to contraceptives, access to reproductive health services, abortion, sexual and gender-based violence, female genital mutation/cutting and early/forced marriage (optional), HIV/STI, mental health (optional), and nutrition (optional). The survey is for individuals 18 years or older, with some sections specifically for women. Population: Adults Only Length: 13 sections, 152 questions Time to Complete: 15-20 minutes Mode of Administration: Online (e.g., computer-assisted interview) Administered by: Self Administered Language(s): English, Italian, Portuguese, Arabic, Latvian, Russian, German, Spanish, Bahasa Melayu, Czech, Danish, French, Khmer, Swedish (Text)
06/01/2020 12:00 AM EDT

Source: Academic Network for Sexual and Reproductive Health and Rights Policy [Ghent University] (ANSER). Published: 6/2020. COVID-19 may have a profound impact on sexual behaviors, reproductive health, and social life across the world. Shelter-in-place regulations that have extended across the globe may influence condomless sex, exacerbate intimate partner violence, and reduce access to essential reproductive health services. Population-representative research is challenging during shelter-in-place, leaving major gaps in our understanding of sexual and reproductive health during COVID-19. This International Sexual Health And REproductive (I-SHARE) study protocol manuscript describes a common plan for online national surveys and global comparative analyses. Methods: The purpose of this cross-sectional study is to better understand sexual and reproductive health in selected countries during COVID-19 and facilitate multi-national comparisons. Participants will be recruited in selected countries through an online survey. The survey link will be disseminated through local, regional, and national networks. In each country, a lead organization will be responsible for organizing ethical review, translation, and survey administration. The consortium network provides support for national studies, coordination, and multi-national comparison. We will use multi-level modeling to determine the relationship between COVID-19 and condomless sex, gender-based violence, access to reproductive health services, HIV testing, and other key items. This study protocol defines primary outcomes, pre-specified subanalyses, and analysis plans. The I-SHARE study examines sexual and reproductive health at the national and global level. We will use multi-level modeling to examine country-level variables associated with outcomes of interest. This will provide a foundation for subsequent online multi-country comparison using more robust sampling methodologies. Population: Adults Only Language(s): English (PDF)
05/14/2020 12:00 AM EDT

Source: Thalassaemia International Federation (TIF). Published: 5/14/2020. This 34-page document aims to provide a division of risk levels for thalassaemia and sickle cell disease patients with regard to the ongoing COVID-19 pandemic. (PDF)
05/01/2020 12:00 AM EDT

Source: National Institutes of Health (NIH). Published: 5/2020. The National Center for Advancing Translational Services (NCATS) is generating a collection of datasets by screening a panel of SARS-CoV-2-related assays against all approved drugs. These datasets, as well as the assay protocols used to generate them, are being made immediately available to the scientific community on this site as these screens are completed. (Text)
05/01/2020 12:00 AM EDT

Source: B.Next. Published: 5/2020. This 11-page guide maps sensors in commercial products to key vital signs and explores ways to capitalize on the smart products that may supplement digital health efforts in response to COVID-19. (PDF)
04/15/2020 12:00 AM EDT

Source: Government of Canada. Published: 4/15/2020. This web page details the potential benefit of healthcare workers wearing a mask for the full duration of their shift to prevent transmission of unrecognized COVID-19 infection to their patients or other healthcare workers (i.e., for use primarily as source control). (Text)
04/01/2020 12:00 AM EDT

Source: Thalassaemia International Federation (TIF). Published: 4/2020. This 18-page document is an informational guide about blood adequacy and safety during the COVID-19 pandemic, compiled on the basis of official recommendations from internationally recognized bodies. (PDF)
03/01/2020 12:00 AM EST

Source: Thalassaemia International Federation (TIF). Published: 3/2020. This 13-page Haemoglobinopathy Patient Care Pathway suggests changes to be made during the outbreak of COVID-19 in the admittance of patients to haemoglobinopathy day care centers/units/clinics. (PDF)
11/05/2019 12:00 AM EST

Source: B.Next. Published: 11/5/2019. This seven-page document summarizes a workshop held in November 2019 that was motivated by B.Next’s interest in technologies that facilitate timely response to infectious disease outbreaks through the rapid design and manufacture of vaccines against newly emergent pathogens. (PDF)

No hay comentarios:

Publicar un comentario